Erbitux® (cetuximab) in Non-Small Cell Lung Cancer (NSCLC) Panel Discussion

A Panel Discussion among Ten Oncologists

Prepared by Panel Intelligence, LLC

May, 2008

 

Deliverable: Transcript with key findings

study description and objectives

To conduct a panel discussion among oncologists specializing in lung cancer to discuss the anticipated results of ImClone’s phase III clinical trial (“FLEX” trial) of Erbitux® (cetuximab) in non-small cell lung cancer (NSCLC), and how the results could impact treatment of the disease.

§    Understand current treatment practices for NSCLC

§    Discuss the anticipated outcomes from ImClone’s recent phase III clinical trial of Erbitux (cetuximab) in NSCLC (“FLEX” trial)

§    Evaluate the potential clinical benefit of Erbitux in NSCLC treatment practices

§    Determine what clinical evidence the Erbitux trial would need to demonstrate in order for it to be used as a first-line treatment in NSCLC

§    Identify the patient population that could benefit from Erbitux

§    Describe the possible impact Erbitux could have on the use of Avastin® (bevacizumab)

§    Identify possible barriers and facilitators to treatment with Erbitux

§    Review the potential cost and reimbursement issues for Erbitux

 

 Companies and Products Mentioned in This Report: 

Company

Ticker Symbol

Product(s)

Genentech

GNE

Avastin® (bevacizumab

ImClone

IMCL

Erbitux® (cetuximab)


Inclusion Criteria

Inclusion Criteria

 

§    US-based oncologists

§    Training and board-certified in oncology

§    2 to 30 years of experience post-training

§    From academic medical centers and community hospitals

§    Treat a significant number non-small cell lung cancer (NSCLC) patients per month

§    Must spend at least 50-75% of time in clinical practice

§    Can not have affiliations with ImClone or Bristol-Myers Squibb and can not have participated in this clinical trial, and potentially other clinical trials about this drug for the treatment of NSCLC

 

Panelists' Institutions

Primary Practice

State

Dartmouth-Hitchcock Medical Center

NH

Hospital of the University of Pennsylvania

PA

M.D. Anderson Cancer Center

FL

Memorial Sloan Kettering

NY

OSF Saint Anthony Medical Center

IL

Private Practice

CA

Private Practice

ID

Private Practice

IN

University of Minnesota

MN

VA Medical Center

WV


Print Abstract

For additional information on this study or to purchase, please call:

Discussion
Oncology
Panel Intelligence, LLC, 150 Cambridgepark Drive, 7th Floor, Cambridge, MA 02140 617 532 5700